Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Foundation Medicine, Inc.
Traded as NASDAQ: FMI
Headquarters Cambridge, Massachusetts, United States
Key people
  • Troy Cox (CEO)
  • Steve Kafka (COO)
  • David Daly (CCO)
Products FoundationOne FoundationOne Heme FoundationACT FoundationFocus CDxBRCA
Owners Hoffmann-La Roche (56%, 2015)
Number of employees
417 (March 2016)
Website Official website

Foundation Medicine, Inc. is a public American company based in Cambridge, Massachusetts which develops, manufactures and sells genomic analysis diagnostics for solid and circulating cancers. The company's tests are based on next-generation sequencing technology.

Foundation Medicine went public in August 2013; its stock is traded on the New York Stock Exchange under the symbol FMI. In 2015, revenue reached $93 million. As of March 2016, the company had 417 employees.

The company's flagship product was FoundationOne, followed by the FoundationOne Heme diagnostic test being for blood cancers.

In November and December 2014, the company established agreements with COTA (Cancer Outcomes Tracking and Analysis) and Flatiron Health, respectively, aimed at increasing the volume of genomic and clinical patient data available to it. In 2015, Roche announced a plan to purchase a 56.3% stake in the company through a US$780,000,000 purchase of newly issued shares. Roche also announced an intention to invest US$400,000,000 toward Foundation Medicine's operations, development and R&D activities.

Foundation Medicine also has business agreements with Johnson & Johnson and Novartis.

The company's chief executive officer (CEO) is Troy Cox. The company's chief operating officer (COO) is Steve Kafka. The company's chief commercial officer (CCO) is David Daly.


Investment goal date:
Dividends reinvested
Foundation Medicine, Inc. FMI report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-07
--
--
Q4 2017
2018-02-23
--
--
Q4 2017
2018-02-20
--
--
Q3 2017
2017-11-01
0.0000
0.0000
Q2 2017
2017-08-01
-1.2400
-1.2400
Q1 2017
2017-05-09
-1.3100
-1.3100
Q4 2016
2017-02-22
-1.0200
-1.0200
Q3 2016
2016-11-02
-0.9000
-0.9000
Q2 2016
2016-08-02
-0.8400
-0.8400
Q1 2016
2016-05-03
-0.5000
-0.5000
Q4 2015
2016-02-23
-0.5500
-0.5500
Q3 2015
2015-11-03
-0.6000
-0.6000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ALLIANCEBERNSTEIN L.P.
788860
BlackRock Fund Advisors
892144
BlackRock Inc.
1335539
BlackRock Institutional Trust Company, N.A.
328677
Chevy Chase Trust Holdings, Inc.
1096489
Discovery Group I, LLC
1304913
GILDER GAGNON HOWE & CO LLC
1610865
GROUP ONE TRADING, L.P.
296359
LORD, ABBETT & CO. LLC
235455
Murphy Michael R
1574711
OPPENHEIMER & CO INC
675040
Parallax Volatility Advisers, L.P.
263800
PIONEER INVESTMENT MANAGEMENT INC
325642
STATE STREET CORP
234960
Vanguard Group, Inc
583496
Major Shareholders
Name Relationship
Total Shares
Holding stocks
ROCHE HOLDINGS INC
72.9100% (20604288)
FMI /
JONES EVAN/ FA
0.0900% (25552)
CASM / FLDM / FMI / VCYT /
BYERS BROOK H
0.1300% (37020)
CDNA / FMI / PACB / VCYT /
DOUGHERTY MICHAEL R
0.0900% (24789)
LEVIN MARK J
0.0600% (17462)
EBIO / FMI /
Borisy Alexis
0.2600% (73173)
FMI /
Daly David
0.4100% (116261)
FMI /
Pellini Michael J
0.9500% (267228)
FMI /
KRENITSKY KEVIN
0.5000% (140611)
ENZ / FMI /
Kleiner Perkins Caufield & Byers XIV, LLC
0.1300% (37020)
FMI /
Schenkein David P
0.0800% (23326)
AGIO / BLUE / FMI /
Miller Vincent A.
0.4200% (119984)
FMI /
Yeshwant Krishna
0.0200% (5786)
FMI /
Kafka Steven J.
0.3200% (90987)
FMI /
Ryan Jason
0.2200% (62332)
FMI /
Hesslein Robert W.
0.4200% (118228)
FMI /
Google Ventures 2011, L.P.
8.6500% (2444653)
FMI /
Cox Troy
0.8900% (251058)
FMI /
% ()